Dr. Jessica T. Leonard, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Northeastern Ohio University College of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 76
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Northeastern Ohio University College of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OR license MD155787 -
Hematology & Oncology Physician
OR license MD155787
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
Medical groups
- University Professional Services (1,724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 76
- Services billed
- 621
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 189 | 39 |
| Established patient office or other outpatient visit, 40-54 minutes | 48 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Portland, OR | 78 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Portland, OR | 41 |
| Oxycodone Hcl Other prescribers in Portland, OR | 41 |
| Celecoxib Other prescribers in Portland, OR | 38 |
| Iclusig (ponatinib hcl) | 30 |
| Prednisone Other prescribers in Portland, OR | 28 |
| Gabapentin Other prescribers in Portland, OR | 26 |
| Jakafi (ruxolitinib phosphate) | 24 |
| Eliquis (apixaban) Other prescribers in Portland, OR | 23 |
| Olanzapine Other prescribers in Portland, OR | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $3,708 in total to this clinician.
| Autolus Inc | $3,708 |
|---|
| Honoraria | $3,120 |
|---|---|
| Travel and Lodging | $334 |
| Food and Beverage | $254 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Autolus Inc Dec 5, 2025 | Honoraria in-kind | $3,120 |
| Autolus Inc Dec 5, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $334 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $1,202,963 in research payments for these studies, mostly to the institutions running them.
- A dose-finding phase Ib multicenter study of the oral BCL-2 inhibitor Venetoclax (ABT-199) in combination with standard induction therapy, dasatinib prednisone, and rituximab in adult patients with newly diagnosed and…
AbbVie Inc. - A20-460;Venclexta;Bottle: ABT-199 100mg Yellow Film Coated Tablet 120 Tablets
AbbVie Inc. - A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda Pharmaceuticals U.S.A., Inc. · Active, not recruiting · NCT03589326 - A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies
Novartis Pharmaceuticals Corporation - Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.